Several mitochondrial K
+ channel sub-types have been implicated in protection against ischemic injury
[1], yet to date all such channels remain undefined at the molecular level. Overall, the unique combination of genetics and pharmacologic signatures studied herein are consistent with a conclusion that SLO2 underlies mBK activity and APC-induced protection in both
C. elegans and perhaps in mouse hearts, as well.
While the mBK channel in both
C. elegans and mouse mitochondria displayed similar pharmacological profiles, only the
C elegans channel was activated by Ca
2+. These results are consistent with the observation that
C elegans SLO-2 channels are activated by Ca
2+, while the mammalian Slo2 ortholog is instead activated by Na
+ [28],
[26], and support the hypothesis that the mBK necessary for mitochondrial K
+ transport and APC is derived from SLO2 in both
C elegans and mice. It is interesting that
C. elegans lack a voltage-gated Na
+ channel
[36]. The differing ion-sensitivities between mammals and
C. elegans Slo2 channels may reflect underlying differences in ischemic electrolyte handling
[26], and in this respect, it is noteworthy that the Slo2 channel characteristics appear to reflect this divergence.
It is not yet clear which mammalian SLO2 paralogue may constitute the mBK channel. In fact, both SLO2.1 and SLO2.2 may play important roles, since the optimal sub-cellular localization of each paralogue appears to depend on formation of heteromers with the other
[37],
[12]. Unfortunately, there are currently no pharmacologic tools to distinguish between SLO2.1 and SLO2.2, and although SLO2.1 is blocked by ATP
[11] this effect is overridden by pharmacologic channel activators (similar to mK
ATP[38],
[20]), and it is not known how SLO2 heteromer formation impacts ATP sensitivity.
While in
C. elegans slo-2 was not necessary for protection by IPC, from the perspective of ischemia however, we find it interesting that SLO2.2 is activated by hypercapnia and acidosis
[27] both which protect against IR injury
[39],
[40],
[41]. Of particular interest is the role of acidosis in activating SLO2 since alkalinization of the matrix is a result of an open mitochondrial K
+ channel
[42] and represents a possible mechanism of feedback inhibition. Likewise, the observation that both SLO2.1 and SLO2.2 channels exhibit K
Na activity
[11],
[27] may have implications for mammalian mBK channel activity during ischemia, in which intracellular Na
+ is elevated
[43],
[44]. These commonalities may warrant further investigation into the role of SLO2.1 and SLO2.2 in IPC in a mammalian context.
It is clear from our data that SLO1 is not required for either APC or IPC in worms or in mice. However, our results do not preclude the presence of SLO1 in the mitochondria or a role for SLO1 channels in other protective paradigms. In fact, the
Slo family of K
+ channels exhibits a wide diversity of auxiliary subunits and multimeric assemblies in different tissues
[37], yielding diverse activities, ion/second-messenger sensitivities, and roles in cellular processes
[26]. In particular, SLO1 and SLO2.2 can heteromultimerize yielding a channel with intermediate properties
[12]. For example, SLO1 channel is sensitive to iberiotoxin and SLO2.2 is insensitive to Ca
2+ but a SLO1/SLO2.2 heteromultimer channel is insensitive to iberiotoxin and sensitive to Ca
2+ [12]. Thus, the tissue diversity in BK composition may explain previous pharmacology-based studies suggesting a
Slo1-derived mBK in other tissues
[10]. Similarly,
slo-1 in worms is known to regulate neurotransmitter release at the synaptic junction
[45] where it acts upstream or parallel to syntaxin
[46]. Mutants in either of these genes can alter the effect of anesthetics on behavior
[46]. It is possible that
slo-1 acting through this pathway could indirectly affect mitochondrial function through humoral neurosecretory mechanisms. However, our unpublished results confirm observations that syntaxin mutants, like
slo-1 mutants, are nevertheless able to be effectively preconditioned by isofluorane
[7].
While it is possible that mBK activation may occur directly through anesthetic stimulation, and we have demonstrated that mBK in isolated mitochondria are opened by isofluorane (), it is also possible that activation occurs indirectly via other anesthetic targets such as protein kinases that may co-purify with mitochondria
[8],
[47],
[48]. Such activation would then stimulate mitochondrial K
+ uptake, with subsequent protection from ischemia occurring via downstream mechanisms that are not yet clear. The activation of mitochondrial K
+ channels is proposed to mediate protection via the regulation of the mitochondrial matrix volume, decreasing mitochondrial Ca
2+ uptake and modulating reactive oxygen species generation
[4]. Through these events activation of the mBK might block the formation of the mitochondrial permeability transition pore and subsequent cell death
[4].
In conclusion, the slo-2 gene in worms contributes to a K+ influx pathway at the mitochondrial inner membrane with a nearly identical pharmacologic sensitivity to a repertoire of activators and inhibitors as recombinant SLO2 channels. Furthermore, slo-2 is necessary for APC-induced protection in worms. Conversely, SLO1 does not contribute to the mitochondrial K+ influx pathway studied here, nor is it required for APC or IPC in either worms or mice. We hypothesize that given these results, Slo2 is likely the APC-relevant channel in mice, and our results further suggest that pharmacologic opening of Slo2 elicits protection. These results have the potential to refocus the design of anti-ischemic therapeutics.